Lipoprotein Disorder

Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment of CV risk.

A survey of patients with CVD in Sweden revealed that of 78% of respondents cited a desire for information on sexual health, yet only 5% reported receiving this information.

CHICAGO — Zerlasiran, a novel injectable small interfering RNA molecule, lowered lipoprotein(a) by more than 80% compared with placebo at 36 weeks, according to the results of the ALPACAR trial.

BOSTON — In this Healio video exclusive, Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC, discusses her presentation at the Cardiometabolic Health Congress, “Primary Prevention of CVD: The Sooner the Better?”

PHILADELPHIA — Despite there being few options to directly lower lipoprotein(a) as of yet, measurement is none the less important to identify those who would benefit from improved risk factor control, a speaker reported.

Roche announced its lipoprotein(a) assay received breakthrough device designation from the FDA to identify patients with history of atherosclerotic CVD who may benefit from Lp(a)-lowering therapy currently in development.

The National Lipid Association updated its guidelines concerning the use of lipoprotein(a) in clinical practice, advising that there is a continuous relationship between a patient’s cardiovascular risk and their levels of Lp(a).

The National Lipid Association issued a focused update on its 2019 scientific statement on use of lipoprotein(a) in clinical practice, incorporating new evidence into recommendations for managing patients with high Lp(a).

Data from a cross-sectional study showed that U.S. adults who reported cannabis use had a higher risk for coronary heart disease, MI and stroke compared with nonusers.

In a real-world cohort, people with the highest levels of lipoprotein(a) had the greatest risk for long-term major adverse CV events, regardless of whether they had atherosclerotic CVD at baseline, researchers reported.